Loading...
Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Table of Content

    Volume 31 Issue 10
    26 October 2026
    Research on the role of STING1 in diabetic atherosclerotic blood vessels and retina
    Yi LIU, Wenhua YU, Yunjian SONG, Mingfeng JIN, Xin JIANG, Zhongqun WANG
    2026, 31(10):  1297-1309.  doi:10.12092/j.issn.1009-2501.2026.10.001
    Asbtract ( 19 )   HTML ( 2)   PDF (9139KB) ( 9 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the role of stimulator of interferon genes 1 (STING1) in diabetic atherosclerotic vascular and retinal pathologies. METHODS: Using ApoE?/? mice and STING1?/?/ApoE?/? mice as experimental subjects, the diabetic models were established by intraperitoneal injection of streptozotocin (STZ), with random blood glucose levels >16.7 mmol/L after two weeks. These mice were further fed a high-fat diet for 16 weeks to develop diabetic atherosclerosis models. The successfully modeled mice were divided into the ApoE?/? diabetic group (ApoE?/? + high-fat diet + STZ) and STING1?/?/ApoE?/? diabetic group (STING1?/?/ApoE?/? + high-fat diet + STZ). An additional control group (ApoE?/? + high-fat diet) with atherosclerosis was also established. Lipid metabolism indicators and inflammatory factors were measured using Enzyme-Linked Immunosorbent Assay (ELISA). Morphological changes in aortic plaques and retina were observed through Hematoxylin-Eosin (HE) staining, Masson,s Trichrome (Masson) staining, and periodic acid-Schiff (PAS) staining. Western blotting and immunohistochemical staining were performed on plaques and retina to assess STING1 expression. Furthermore, neovasculature formation in arterial plaques and retinal tissues was evaluated using antibodies CD31, CD34, and LYVE-1. RESULTS: Compared with the control group, diabetic mice exhibited elevated levels of blood lipids and inflammation, increased atherosclerotic plaque area, reduced collagen deposition, thickened retina, and increased acellular capillaries. STING1 expression was also significantly upregulated in both plaques and retina. In contrast, STING1 deficiency reduced plaque area and retinal thickness and increased intraplaque collagen content. In addition, knocking out STING1 inhibited neovascularization within plaques and the retina. STING1 expression levels were positively correlated with both aortic plaque area and retinal thickness (P <0.05). CONCLUSION: STING1 expression significantly influenced the progression of diabetic atherosclerotic plaques, pathological changes in retinal tissue, and angiogenesis. This suggests that STING1 may serve as a common molecular bridge for diabetic vascular and retinopathy, providing a potential target for developing novel therapeutic strategies.

    Study on the mechanism of Shenshao tablets based on heart-intestinal flora axis in the treatment of chronic heart failure
    Qiujin JIA, Lu FAN, Haomin ZHANG, Xiaoling WANG, Xiaonan ZHANG, Peng YUAN, Yujie HAO, Wenbao HAN, Zhuo YUAN, Yunjiao WANG, Chao ZHAO, Shichao LYU
    2026, 31(10):  1310-1319.  doi:10.12092/j.issn.1009-2501.2026.10.002
    Asbtract ( 18 )   HTML ( 0)   PDF (5988KB) ( 5 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the mechanism of Shenshao tablet in treating chronic heart failure (CHF) from the perspective of gut microbiota. METHODS: The CHF model of rat was established by isoproterenol and randomly divided into control, model, low-/high-dose Shenshao tablet, ginseng stem-leaf saponin, and total glucosides of paeony groups. After 4 weeks, cardiac function, myocardial collagen deposition, and intestinal barrier function were assessed. 16S rDNA sequencing and targeted metabolomics were performed. RESULTS: Compared with control group, there were decreased cardiac function, aggravated myocardial fibrosis, and impaired intestinal barrier in the model group. Shenshao tablet reduced LVEDD, LVESD, and NT-proBNP levels, increased LVEF, decreased myocardial collagen deposition, and lowered serum levels of DAO, D-lactate, and endotoxin. Gut microbiota analysis revealed increased abundances of Melainabacteria phylum and Paraprevotella genus, and decreased Actinobacteria phylum in HF rats. Shenshao tablet increased microbial diversity, enriched beneficial bacteria, reduced Spirochaetes phylum abundance, lowered serum trimethylamine N-oxide, and elevated short-chain fatty acids. CONCLUSION: Shenshao tablet ameliorates myocardial remodeling and intestinal barrier dysfunction in chronic heart failure, with effects superior to its individual components. Its cardioprotective mechanism may be associated with the regulation of gut microbiota structure and metabolites.

    The mechanism of Qihong Tongluo Granule in regulating mitochondrial dynamics disorder and improving cerebral ischemia-reperfusion injury
    Qi LOU, Anran GUO, Shuting YUAN, Ting WANG, Huiyu JIA, Xiaoyu ZHU, Dongmei YANG, Manqin YANG, Shengyong LUO
    2026, 31(10):  1320-1329.  doi:10.12092/j.issn.1009-2501.2026.10.003
    Asbtract ( 13 )   HTML ( 0)   PDF (10956KB) ( 4 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To investigate the regulatory effect of Qihong Tongluo Granule on mitochondrial dynamics disorder after cerebral ischemia-reperfusion injury. METHODS: One hundred and eight SD rats were selected and randomly divided into six groups: sham, model, ginadol (0.022 g/kg), and high-, middle- and low-dose Qihong Tongluo Granule group (10.8, 5.4, 2.7 g/kg). The occlusion model of middle cerebral artery (MCAO) was established by thread embolism method. Reperfusion was resumed after 2 h of ischemia, and the rats were administered once a day by gavage for 2 consecutive days before the surgery and for 3 consecutive days after the surgery. After 72 hours of reperfusion, the mNSS and the rotarod test were used to assess the neurological function impairment; the Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL) method was used to determine the apoptosis of cortical tissue cells; using fluorescence microplate to measure the mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels; the biochemical kit was used to detect the ATP and the activities of mitochondrial respiratory chain complexes I-IV; the ultrastructural changes of mitochondria were observed through transmission electron microscope (TEM) ; western-blot was used to measure the protein expressions of cystein-asparate protease-3 (Caspase-3), B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax), dynamin-related protein 1 (Drp1), fission protein 1 (Fis1), optic atrophy 1 (Opa1), mitofusin 1 (Mfn1), mitofusin 2 (Mfn2). RESULTS: Compared with the model group, QHTLG could significantly reduce the mNSS score, increase the time rats spent on the rotating rod, inhibit the apoptosis rate of cortical tissue cells, reduce the expression of Caspase-3 and Bax proteins, and promote the expression of Bcl-2 protein; obviously increase MMP and ATP production, reduce ROS levels, and increase the activity of respiratory chain complexes I-IV; remarkedly alleviate mitochondrial damage, inhibit the expression of Drp1 and Fis1 proteins, and increase the expression levels of Opa1 and Mfn1/2 proteins. CONCLUSION: QHTLG has a significant protective effect on cerebral ischemia-reperfusion injury in rats. The mechanism may be related to regulating mitochondrial dynamic balance, thereby reducing oxidative stress and cell apoptosis.

    Mechanistic study on the hepatoprotective effects of Gurigumu-13 Pill against drug-induced liver injury based on metabolomics and metagenomics
    Yongqi HUANG, Longshan ZHAO, Dongdong ZHAO, Yukun BO, Dan YANG, Jingjing GUO, Xuemiao YANG, Yanan LV, Shumin LI, Haiyan ZHANG, Guodong WU, Ming AN
    2026, 31(10):  1330-1341.  doi:10.12092/j.issn.1009-2501.2026.10.004
    Asbtract ( 9 )   HTML ( 0)   PDF (6858KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To evaluate the hepatoprotective effect of Gurigumu-13 Pill against acetaminophen (APAP)-induced drug-induced liver injury (DILI) and to explore its underlying mechanisms. METHODS: An APAP-induced DILI model was established in Sprague-Dawley rats by oral administration. Liver injury was assessed by measuring serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, along with histopathological examination. Fecal microbiota composition was analyzed using metagenomic sequencing, and metabolic reprogramming was investigated through untargeted metabolomics. RESULTS: Compared with the model group, Gurigumu-13 Pill significantly reduced serum ALT and AST levels and improved hepatic histopathology. It markedly reversed APAP-induced gut microbiota dysbiosis, enhanced microbial diversity, and modulated metabolic pathways associated with DILI, thereby promoting the restoration of metabolic homeostasis. CONCLUSION: Gurigumu-13 Pill exerts a pronounced hepatoprotective effect by restoring intestinal microecological balance and re-establishing metabolic homeostasis.

    Endoplasmic reticulum stress regulates ferroptosis in hepatocellular carcinoma via TRIB3: evidence from an integrated multi-omics analysis
    Lin CAI, Anqi WANG, Shuojiao LI, Peng RAO, Yue TANG, Wenxian YU, Haiyun ZHOU, Guoping SUN, Jiatao LIU
    2026, 31(10):  1342-1352.  doi:10.12092/j.issn.1009-2501.2026.10.005
    Asbtract ( 13 )   HTML ( 0)   PDF (20685KB) ( 3 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To explore the molecular interaction between endoplasmic reticulum stress (ERS) and ferroptosis in hepatocellular carcinoma (HCC), and provide potential targets for the diagnosis and treatment of HCC. METHODS: Differentially expressed genes (DEGs) in endoplasmic reticulum stressed HCC cells were identified by RNA sequencing, these DEGs were then intersected with the ferroptosis dataset (FerrDb database) to obtain differentially expressed ferroptosis-related genes (DFRGs) under ERS. Key genes were identified through the construction of a PPI network, GO and KEGG analyses. Disease correlation and ROC curve analyses were also performed for the key genes. Western blotting, qRT-PCR, Immunohistochemistry and immunofluorescence evaluated the effect of Tribbles homolog 3 (TRIB3) on ferroptosis in HCC cells under ERS. RESULTS: A total of 57 DFRGs were screened. PPI analysis identified 15 key DFRGs, while ROC curve and Kaplan-Meier analysis further revealed that SESN2, SLC1A4, ATF4, DDIT3, HSPA5, SLC7A11, ASNS, and TRIB3 may hold diagnostic and prognostic value for HCC patients. In addition, ERS could significantly increase the expression of TRIB3 and simultaneously decrease the ferroptosis activity of liver cancer cells, while ferroptosis-related molecules expression was obviously increased through knocking down TRIB3. CONCLUSION: In this study, TRIB3 was identified and validated as a novel core gene involved in the modulation of ERS and ferroptosis. TRIB3 may serve as a prognostic indicator and potential therapeutic target for HCC.

    Optimization of a Gastrodia elata multi-component combination based on mixture design and its protective effects against corticosterone-induced cellular stress injury
    Xin WANG, Dong PEI, Zhaoyang ZENG, Duolong DI
    2026, 31(10):  1353-1362.  doi:10.12092/j.issn.1009-2501.2026.10.006
    Asbtract ( 15 )   HTML ( 0)   PDF (18549KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To identify an exploratory candidate ratio of Gastrodia elata polysaccharide (GEP) and Gastrodia elata ethanolic extract (GET) in corticosterone (CORT)-induced PC12 and HT22 cellular stress models and to evaluate associated changes in oxidative stress, mitochondrial membrane potential, and related proteins. METHODS: CCK-8 assays were used to determine CORT conditions and the working concentrations of GEP and GET. Cell viability, total superoxide dismutase (T-SOD), and malondialdehyde (MDA) were integrated by multi-response desirability optimization. The candidate combination was validated in both cell lines. Reactive oxygen species (ROS), mitochondrial membrane potential (ΔΨm), and Nrf2, PINK1, and Parkin expression were assessed. RESULTS: CORT was used at 400 μmol/L in PC12 cells and 200 μmol/L in HT22 cells. GEP and GET working solutions were 200 μg/mL and 10 μg/mL, respectively. The three quadratic mixture models were not statistically significant (P=0.549, 0.500, and 0.181), and all predicted R2 values were 0. The composite desirability was 0.632, yielding an exploratory GEP-to-GET working-solution ratio of 71:29 (V/V). The candidate combination increased cell viability and improved ROS and ΔΨm in both models (P<0.05 or P<0.01). During model development, MDA decreased and T-SOD increased. Treatment was also accompanied by higher Nrf2, PINK1, and Parkin protein expression (P<0.05 or P<0.01). CONCLUSION: The 71:29 candidate combination alleviated CORT-induced cellular stress injury in vitro. The findings support a combination advantage and mechanistic leads but do not establish supra-additive synergy, activation of a complete Nrf2-PINK1/Parkin pathway, or antidepressant efficacy in vivo.

    External validation of population pharmacokinetic models for linezolid in adult patients
    Qiu FANG, Shuangmiao JIANG, Jing WANG, Xuemei LUO, Lu JIN, Huaijun ZHU
    2026, 31(10):  1363-1376.  doi:10.12092/j.issn.1009-2501.2026.10.007
    Asbtract ( 18 )   HTML ( 0)   PDF (2627KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To evaluate the predictive performance of published population pharmacokinetic models for linezolid and explore their applicability and limitations. METHODS: A systematic search was conducted in databases such as PubMed and CNKI (up to June 2025), and model information was extracted. Steady-state blood concentration data from 223 samples of 111 adult infected patients at Nanjing Drum Tower Hospital were collected for external validation using goodness-of-fit tests, prediction error tests, and visual predictive checks. RESULTS: A total of 25 population pharmacokinetic models for linezolid were included in this study. Validation results showed that the population prediction performance was suboptimal, with the best model having an R2 of only 0.28. The prediction error within the ±30% range (F30) was below 35%, and none of the models met the established standards. However, individual prediction capability was relatively good, with the best model achieving an R2 of 0.92 and an IF30 value as high as 82.11%, indicating that most models demonstrated good prediction ability. Subgroup analysis suggested that specific clinical environments could improve population predictions, and high-precision individual prediction models showed strong stability. CONCLUSION: The existing population pharmacokinetic models for linezolid exhibit large prediction errors and limited extrapolation ability in patients at this center, with insufficient clinical applicability. Individual predictions can help improve model accuracy. Future research should incorporate more covariates, expand the sample size of special populations, and enhance model generalizability through prospective studies.

    Predicting dual response failure to semaglutide in obese type 2 diabetes: development and validation of a visual scoring system
    Fandong MENG, Jingjing FAN, Xin LIU, Lulu KONG
    2026, 31(10):  1377-1384.  doi:10.12092/j.issn.1009-2501.2026.10.008
    Asbtract ( 12 )   HTML ( 0)   PDF (1600KB) ( 6 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To develop and validate a nomogram-based scoring system for predicting the risk of failing to achieve dual response in glycemic control and weight loss with semaglutide in obese type 2 diabetes mellitus (T2DM) patients. METHODS: A total of 347 obese T2DM patients who received subcutaneous semaglutide injection therapy for the first time at our endocrinology department between January 2023 and January 2025 were enrolled. Based on the treatment timeline, patients recruited from January 2023 to June 2024 were assigned to the training set (n=243), while those recruited from July 2024 to January 2025 were assigned to the validation set (n=104). According to dual response status, patients in the training set were further divided into a response group (n=159) and a non-response group (n=84). Univariate and multivariate logistic regression analyses were employed to identify risk factors for failing to achieve the dual response, and a nomogram prediction model was constructed based on these factors. RESULTS: Lower BMI (OR: 0.533, 95%CI: 0.381-0.748), longer duration of diabetes (OR: 1.591, 95%CI: 1.294-1.957), lower FBG (OR: 0.349, 95%CI: 0.238-0.511), lower HbA1c (OR: 0.380, 95%CI: 0.241-0.599), and lower visceral fat content (OR: 0.989, 95%CI: 0.981-0.997) were identified as independent risk factors for failing to achieve the dual response (all P<0.05). Model validation demonstrated good performance: Hosmer-Lemeshow test results for the training and validation sets were (χ2=12.463, P=0.132) and (χ2=7.753, P=0.445), respectively, indicating good calibration, which was further supported by calibration curves closely aligning with the ideal line. The areas under the ROC curve (AUC) were 0.956 (95%CI: 0.940-0.971) for the training set and 0.814 (95%CI: 0.790-0.838) for the validation set. Decision curve analysis showed positive net benefits across a threshold probability range of 0% to 100%. CONCLUSION: BMI, duration of diabetes, FBG, HbA1c, and visceral fat content are closely associated with the likelihood of achieving dual response to semaglutide regarding glycemic control and weight loss in obese T2DM patients. The nomogram model constructed based on these indicators demonstrates good predictive performance.

    Clinical outcomes of glucocorticoid tapering and withdrawal after remission in isolated polymyalgia rheumatica: a single-center retrospective study
    Lanlan JIA, Dandan FENG, Xiaowan WANG, Liang XU
    2026, 31(10):  1385-1391.  doi:10.12092/j.issn.1009-2501.2026.10.009
    Asbtract ( 14 )   HTML ( 0)   PDF (1030KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    AIM: To retrospectively analyze the extended follow-up data from a registered randomized controlled trial initiated at our center in 2018 involving low-dose glucocorticoid (GC) treatment for isolated polymyalgia rheumatica (PMR), and to investigate GC tapering and discontinuation after clinical remission, as well as relapse following GC withdrawal. METHODS: A total of 86 treatment-na?ve patients with isolated PMR who were hospitalized at our center between January 2018 and December 2023 and underwent long-term follow-up were included. The median follow-up duration was 19 months [interquartile range (IQR), 10.0-53.0 months]. According to the treatment allocation in the original registered trial, patients were divided into three groups: GC monotherapy (n=25), GC plus methotrexate (MTX, 10 mg/week; n=32), and GC plus Tripterygium wilfordii polyglycosides (TW, 20 mg three times daily; n=29). All patients received an initial prednisone dose of 10 mg/day. Different from the prespecified standardized tapering protocol in the original RCT, GC doses were gradually tapered on an individualized basis according to clinical symptoms and inflammatory markers after achieving clinical remission. Subsequently, all patients received GC monotherapy for maintenance and further tapering.GC tapering, discontinuation, and subsequent clinical outcomes were evaluated, and potential factors associated with relapse after GC withdrawal were explored. RESULTS: All patients in the three treatment groups achieved clinical remission following induction therapy. The median time to remission was 6 months in all three groups, with IQRs of 3.0-7.5, 3.0-7.5, and 3.0-8.8 months in the GC monotherapy, GC plus TW, and GC plus MTX groups, respectively, with no statistically significant difference among groups. Overall, 47 patients (54.7%) discontinued GC therapy. The median interval from clinical remission to complete GC discontinuation was 20.8 months (IQR, 14.9–36.5 months). The GC discontinuation rates were 64.0%, 51.7%, and 50.0% in the GC monotherapy, GC plus TW, and GC plus MTX groups, respectively, with no statistically significant difference (P= 0.532). Among patients who discontinued GC therapy, the relapse rates during follow-up were 0% (0/16), 20.0% (3/15), and 12.5% (2/16), respectively, with no statistically significant difference among groups (P=0.181). Of the 47 patients who discontinued GC therapy, 5 (10.6%) experienced relapse after withdrawal, with a median time to relapse of 10.8 months (range, 6-24 months). Exploratory analysis showed that baseline neutrophil-to-lymphocyte ratio (NLR) was higher in relapsed patients than non-relapsed patients (median, 7.2 vs. 3.3; P=0.034). CONCLUSION: Gradual GC tapering and eventual discontinuation are feasible in some patients with isolated PMR after achieving clinical remission, although relapse may occur following withdrawal. Exploratory findings suggest elevated baseline NLR may correlate with post-withdrawal relapse. Given the limited number of relapse events, its predictive value needs further validation in larger prospective cohorts, and it is not recommended for direct clinical risk stratification at present.

    Progress in the use of rituximab in interstitial lung disease
    Tianyun YANG, Zhihong CHEN
    2026, 31(10):  1392-1399.  doi:10.12092/j.issn.1009-2501.2026.10.010
    Asbtract ( 10 )   HTML ( 0)   PDF (569KB) ( 4 )  
    Figures and Tables | References | Related Articles | Metrics

    Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases (CTD), and conventional pharmacotherapy yields unsatisfactory therapeutic outcomes. In recent years, the application of therapeutic approaches such as biologics has improved the prognosis of such patients. Rituximab (RTX) is a chimeric human-mouse monoclonal antibody specifically targeting the CD20 antigen on the surface of B lymphocytes. Clinical practice has demonstrated that RTX serves as a valuable therapeutic option for patients with various connective tissue disease-related interstitial lung disease (CTD-ILD) who fail glucocorticoid and immunosuppressive therapy. This article reviews the mechanism of action of RTX and its application in connective tissue disease-associated ILD.

    Research progress on enhancement of immunotherapy sensitivity of lung cancer by PD-1/PD-L1 pathway with traditional Chinese medicine and natural products
    Siyuan ZHANG, Xiangqi WANG, Yi YIN
    2026, 31(10):  1400-1409.  doi:10.12092/j.issn.1009-2501.2026.10.011
    Asbtract ( 15 )   HTML ( 0)   PDF (2514KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    Lung cancer (LC) is a globally prevalent type of cancer, mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 50% of NSCLC patients have developed metastasis at the initial diagnosis, resulting in limited treatment options for advanced stages. Immunotherapy has become the major breakthrough, among which PD-1/PD-L1 inhibitors block the binding between PD-1 and PD-L1, restore T cell activity, and inhibit tumor immune escape. Natural product-derived PD-1/PD-L1 inhibitors (PDNP) have the advantages of good oral bioavailability, strong tissue permeability, and low cost, and can regulate the tumor microenvironment and enhance the sensitivity of immunotherapy. This review summarizes the latest progress of PDNP in the treatment of LC, including flavonoids, alkaloids, terpenoids and other types of compounds. These compounds exert anti-lung cancer effects by directly or indirectly regulating the PD-1/PD-L1 pathway: directly blocking the binding of PD-1 and PD-L1; regulating upstream signaling pathways such as Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3), nuclear factor kappa B (NF-κB), and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR); and indirectly regulating the activation state of the PD-1/PD-L1 pathway by modulating the tumor microenvironment. In addition, this review discusses the anti-lung cancer effects of various traditional Chinese medicines and their active ingredients in regulating the PD-1/PD-L1 pathway, as well as the mechanism of synergistically reducing chemotherapy drug resistance. It aims to provide new ideas for lung cancer treatment and reversing drug resistance, and also offer useful references for the development of new anti-lung cancer drugs.

    Research progress on dotinurad in the treatment of hyperuricemia and gout
    Yuanyuan ZHENG, Yulu BU, Huizhen WU
    2026, 31(10):  1410-1416.  doi:10.12092/j.issn.1009-2501.2026.10.012
    Asbtract ( 14 )   HTML ( 0)   PDF (471KB) ( 3 )  
    Figures and Tables | References | Related Articles | Metrics

    Hyperuricemia, a metabolic disorder syndrome caused by dysregulation of purine metabolism, exhibits a significantly rising prevalence rate in China and has become a major public health concern. Currently available urate-lowering drugs face limitations in safety profiles, necessitating novel therapeutic options. Dotinurad, as a new-generation selective inhibitor of uric acid reabsorption, exerts its therapeutic effect by precisely targeting the urate transporter 1 (URAT1) on the apical membrane of renal proximal tubules. Its molecular mechanism involves the selective inhibition of the URAT1-mediated uric acid Cl-/organic anion exchange reabsorption pathway, thereby promoting uric acid excretion. This agent possesses pharmacokinetic characteristics including low volume of distribution and high plasma protein binding, ensuring long-lasting stable blood concentrations. It is primarily metabolized via glucuronidation/sulfation conjugation. Dosage adjustment is not required for patients with mild-to-moderate hepatic or renal impairment. Age and sex differences do not significantly affect its pharmacokinetics, and it carries a low risk of drug-drug interactions. This article reviews the fundamental profile, pharmacological research, clinical efficacy, and safety of dotinurad, aiming to provide expanded perspectives and alternatives for managing hyperuricemia with gout.

    Regulatory role of exosome in the inflammatory mechanism of COPD and research progress of drug intervention
    Haiyi NIE, Qi GUO, Huanhuan ZHANG, Zhangbo SONG, Mengyuan WU, Zhiming MIAO, Yangyang LI, Pin LIU, Wenxing YONG, Liying ZHANG
    2026, 31(10):  1417-1429.  doi:10.12092/j.issn.1009-2501.2026.10.013
    Asbtract ( 9 )   HTML ( 0)   PDF (793KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics

    Chronic obstructive pulmonary disease (COPD) is a prevalent and life - threatening chronic respiratory disease worldwide, characterized by persistent and incompletely reversible airflow limitation, with inflammatory responses occurring throughout the entire disease course. Inflammatory cells such as neutrophils and macrophages secrete a variety of inflammatory mediators, which activate relevant signaling pathways and accelerate disease progression. As a crucial component of extracellular vesicles, exosome range in diameter from 30 to 150 nm and can carry bioactive substances to participate in intercellular communication. Studies have demonstrated that exosome play a pivotal role in the pathological progression of inflammatory responses in COPD: they not only transport nucleic acids, proteins, and other molecules to regulate inflammatory reactions but also hold great promise as diagnostic biomarkers and potential therapeutic targets for COPD and its associated inflammatory responses. This review systematically summarizes the mechanisms underlying the role of exosome in COPD - related inflammatory responses, elaborates on the relevant inflammatory signaling pathways in depth, and highlights the latest research advances in drug - based prevention and treatment strategies targeting these mechanisms. The aim is to provide novel theoretical foundations and intervention targets for the clinical management of COPD, thereby facilitating the development of more effective preventive and therapeutic approaches.

    Research progress of drugs in the treatment of cerebral ischemia-reperfusion injury through the JNK signaling pathway
    Haobo GAO, Hifsa Bibi, Pengcheng ZHU, Hongtu TAN, Tao WU
    2026, 31(10):  1430-1440.  doi:10.12092/j.issn.1009-2501.2026.10.014
    Asbtract ( 12 )   HTML ( 3)   PDF (615KB) ( 4 )  
    Figures and Tables | References | Related Articles | Metrics

    After the blood supply of the brain is limited, the secondary tissue injury caused by the reperfusion is called cerebral ischemia-reperfusion injury (CIRI). In this pathological process, the JNK signaling pathway, as a key signal transduction pathway, has a decisive impact on the apoptosis of neurons, the maintenance of cell homeostasis and other physiological activities. The activation of the JNK signaling pathway is closely related to apoptosis, blood-brain barrier destruction and inflammatory response in CIRI. Therefore, this pathway is regarded as a potential target for the treatment of CIRI. This review summarizes recent research progress on the therapeutic effect of drugs on CIRI by regulating the JNK signaling pathway, in order to provide theoretical support and innovative research directions for the treatment of cerebral ischemia-reperfusion injury.